source
- Roivant's autoimmune drug brepocitinib succeeds in two pivotal trials, paving way for 2027 filingRoivant Sciences said its autoimmune drug brepocitinib met primary goals in two pivotal studies. The trials, which evaluated the drug in separate autoimmune indications, showed statistically signi…
- Mark Cuban’s Cost Plus Drugs plans to enter custom rare-disease drug marketMark Cuban says his company Cost Plus Drugs will expand beyond generic medicines into the custom‑made rare disease space. The firm, which currently buys generic drugs and sells them directly to con…